Diabetes Care· 2018Q1· Guideline
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- 3,526citations
- Q1SCImago
- 2018year
Short summary
New 2018 ADA/EASD guidelines recommend SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular benefit for type 2 diabetes patients with clinical cardiovascular disease, and SGLT2 inhibitors for those with chronic kidney disease or heart failure.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine